Fact CheckerSign in

NCT07568379Not yet recruiting

Multidimensional Study of Dyspnea at Rest, During Exertion, Self-induced Through a Virtual Reality Scenario, and Its Placebo Effect in Patients With COPD and Control Subjects.

Source: ClinicalTrials.gov · Last updated 5 May 2026

Brief summary (registry, in English)

This quasi-experimental laboratory study aims to describe and compare the multidimensional experience of dyspnea at rest and during exertion in patients with chronic obstructive pulmonary disease (COPD) and healthy controls. The study integrates neurophysiological, somatosensory, and psychological assessments, including prefrontal cortex activity (fNIRS), quantitative sensory testing (QST), and immersive virtual reality (VR) scenarios. Additionally, the study evaluates the modulation of dyspnea perception through expectation mechanisms and placebo intervention using high-flow nasal cannula (HFNC). The ultimate goal is to better understand the multidimensional and neurocognitive mechanisms underlying dyspnea.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
80 (estimated)
First submitted
23 Apr 2026
Start date
Apr 2026
Primary completion date
Jun 2027
Lead sponsor
University of Deusto
Diseases
COPD
NCT number
NCT07568379

What you commit to

  • Study type: Observational
  • Planned participants: 80
  • From Apr 2026 to the primary completion date, Jun 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Medication affecting respiratory function

Other illness

  • Severe cardiac, neurological, or psychiatric disease
  • Other respiratory diseases
  • Recent infections

Other

  • COPD patients:
  • Recent exacerbation
  • Use of ventilatory support (except CPAP)
    • Heatlhy subjects:
  • Respiratory symptoms
  • Substance abuse

Who the study is looking for

  • COPD:
  • Diagnosed COPD (FEV1/FVC \< 0.7 post-bronchodilator)
  • GOLD stage 2-4
  • Clinically stable
  • Signed informed consent
    • Healthy subjects:
  • Normal pulmonary function
  • No chronic diseases
  • Non-smoker or long-term ex-smoker

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Univesity of Deusto
Coordinator of this site? Confirm its status
San SebastiánSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.